Skip to content

aptamers

Aptamers as protein-protein interaction inhibitors

Protein-protein interactions were once considered undruggable. Our tailored aptamer selection approach is proving this isn’t so. Targets such as transcription factors, immune checkpoints in oncology, infectious disease agents, and…

The stability of aptamers

One of the key benefits of using aptamers instead of antibodies is how you store and use your reagent. Over the past 60 years the stability of oligonucleotides has…

Appointment of Interim Chief Commercial Officer

09/01/2023 Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, today announces the appointment of Derek Smith as Interim Chief Commercial Officer,…

Custom aptamers: 5 factors to consider before you begin

From drug screening to critical assay reagents and as targeted therapeutics, aptamers are increasingly being employed across the discovery and development pipeline. Despite the large catalogues of antibodies, aptamers and…

Aptamer-enhanced gene therapy delivery

Gene therapy is the future for the treatment of several, often life-threatening conditions. Several gene therapy assets are currently under trial targeting cancers, sensory organs, blood disease, and rare…